30
Participants
Start Date
February 13, 2024
Primary Completion Date
May 7, 2025
Study Completion Date
November 15, 2025
Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC
Dolutegravir (DTG) 50 mg orally BID (\~12 hours apart) plus TDF/3TC, from study week 6 until 2 weeks after completion of TB treatment: Morning dose DTG 50 mg QD plus TDF/3TC from study-supplied ARV regimen. Evening dose: DTG 50 mg orally QD from study-supplied source.
DTG 50 mg orally QD plus TDF/3TC
DTG 50 mg orally QD plus TDF/3TC from two weeks after completion of TB treatment to end of study (week 48).
2HPZM
Daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen
2HPM
Daily rifapentine-moxifloxacin plus isoniazid regimen
Durban International CRS (Site # 11201), Westridge
South African Tuberculosis Vaccine Initiative (SATVI) CRS (Site # 31793), Worcester
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site # 31802), Bangkok
University of Cape Town Lung Institute (UCTLI) CRS (Site # 31792), Mowbray
Collaborators (2)
ViiV Healthcare
INDUSTRY
Mylan Inc.
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH